Skip to main content
. Author manuscript; available in PMC: 2015 Apr 30.
Published in final edited form as: Sci Transl Med. 2015 Feb 25;7(276):276ra26. doi: 10.1126/scitranslmed.3010101

Fig 7. Calbindin immunofluorescence of cerebellar paravermis in 6-month-old cats.

Fig 7

Untreated NPC cats (B) showed a severe loss of Purkinje cells compared to normal control cats (A). Subcutaneous (SC) HPβCD administration at a dose of 8000 mg/kg resulted in increased Purkinje cell survival (D), whereas cats receiving 1000 mg/kg SC HPβCD were indistinguishable from untreated NPC cats (C). Cats treated with IC HPβCD at 30 mg or greater (H) resulted in substantial Purkinje cell survival. In contrast, 3.8 mg IC HPβCD (G) or 120 mg IC HPβCD given either presymptomatically (E) or postsymptomatically (120 mg IC late) (F) resulted in small but non-significant increases in Purkinje cell number compared to untreated NPC cats. Scale bar = 200 microns.